The Pink Sheet’s regularly updated list of products containing new active substances that have been approved for marketing in the EU under the centralized authorization procedure now includes nine new products – Kostaive, Nemluvio, Welireg, Andembry, Beyonttra, Hetronifly, Kavigale, Lazcluze and Siiltibcy.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include nine new products, one of which is Kostaive (zapomeran), CSL/Arcturus Therapeutics’ self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older.
